Skip to main content
. 2016 Jan 27;16:30. doi: 10.1186/s12879-016-1345-1

Table 5.

Treatment Emergent Adverse Events by treament group, causality and intensity

ARV naïve group (n=18) Lopinavir group (n=16)
AL suspected AL not suspected AL suspected AL not suspected
Mild Moderate Mild Moderate Mild Moderate Mild Moderate
Gastrointestinal disorders
 Abdominal pain 1
 Constipation 1
 Decreased appetite 1 1
 Diarrhoea 1 1 2 1
 Dyspepsia 2
 Epigastric discomfort 1 1
 Flatulence 3
 Gastrooesophageal reflux disease 1
 Nausea 3 2
 Vomiting 2
Infections and infestations
 Gingivitis 1
 Influenza-like illness 3 2
Nervous system disorders
 Dizziness 1 1
 Headache 4 3 1 3 2
 Presyncope 1
Respiratory, thoracic and mediastinal disorders
 Nasal congestion 1
 Rhinorrhoea 1
Skin and subcutaneous tissue disorders
 Abscess 1
 Body tinea 1
 Rash 1 1
 Seborrhoeic dermatitis 1
General disorders and administration site conditions
 Fatigue 1 1
 Injection site reaction 2 3
Musculoskeletal and connective tissue disorders
 Back / neck pain 3
 Muscle twitching 2
Renal and urinary disorders
 Frequency of micturition 1
 Urinary tract infection 1 1
Reproductive system and breast disorders
 Vaginal discharge 1
Immune system disorders
 Seasonal allergy 1
Vascular disorders
 Epistaxis 1
 Hypertension 1 1
Eye disorders
 Uveitis 1
Psychiatric disorders
 Alcoholic hangover
 Self-induced vomiting 1
Metabolism and nutrition disorders
 Hypercholesterolaemia
 Oedema peripheral 1
Injury, poisoning and procedural complications
 Skin wounds 1
TOTAL 15 0 19 1 12 0 27 3